Compare PGEN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | ZLAB |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | China |
| Employees | 47 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2013 | 2017 |
| Metric | PGEN | ZLAB |
|---|---|---|
| Price | $7.70 | $26.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $8.33 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 3.7M | 767.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 0.03 | N/A |
| Revenue | $230,981,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $1,115.92 | $9.75 |
| Revenue Next Year | $81.04 | $26.03 |
| P/E Ratio | $258.83 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $2.99 | $15.96 |
| 52 Week High | $8.04 | $34.72 |
| Indicator | PGEN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.70 | 60.70 |
| Support Level | $6.57 | $16.84 |
| Resistance Level | $7.72 | $27.22 |
| Average True Range (ATR) | 0.27 | 0.90 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 76.41 | 70.98 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.